How many insider trades does FilingIQ track for FBRX?

FilingIQ tracks 98 Form 4 insider transactions for FBRX (Forte Biosciences, Inc.), covering filings from Jun 25, 2020 onwards. 6 of those were filed in the last 90 days.

Are FBRX insiders net buyers or net sellers?

Across the full Form 4 history for FBRX, 18 transactions (18%) were open-market purchases and 3 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does FBRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is FBRX in?

Forte Biosciences, Inc. (FBRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $338.35M.

FBRX insider trading

NasdaqCM Healthcare

Forte Biosciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

18% / 3%

Market cap

$338.35M

About Forte Biosciences, Inc.

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Company website: www.fortebiorx.com

FBRX insider activity at a glance

FilingIQ has scored 98 insider transactions for FBRX since Jun 25, 2020. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 18 open-market purchases and 3 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on FBRX insider trades is 65.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live FBRX trades on FilingIQ Raw filings on SEC EDGAR

Latest FBRX Form 4 filings

Riley Antony A CHIEF FINANCIAL OFFICER

P Nov 21, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for FBRX?: FilingIQ tracks 98 Form 4 insider transactions for FBRX (Forte Biosciences, Inc.), covering filings from Jun 25, 2020 onwards. 6 of those were filed in the last 90 days.
Are FBRX insiders net buyers or net sellers?: Across the full Form 4 history for FBRX, 18 transactions (18%) were open-market purchases and 3 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does FBRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is FBRX in?: Forte Biosciences, Inc. (FBRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $338.35M.

Methodology & sources

Every FBRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.